Invivyd's PEMGARDA maintains effectiveness against XFG variant of SARS-CoV-2.

Invivyd (IVVD) announced positive in vitro neutralization data for PEMGARDA against the dominant XFG variant of SARS-CoV-2. PEMGARDA remains effective against XFG, with no meaningful change to the neutralization activity of pemivibart or VYD2311, the company's next-gen COVID-19 monoclonal antibody candidate. Invivyd estimates that every clinical variant reported since Omicron BA.2 has been susceptible to pemivibart, due to the consistent structural integrity of the epitope targeted by pemivibart.

Invivyd, Inc. (Nasdaq: IVVD) recently announced positive in vitro neutralization data for PEMGARDA against the currently dominant XFG variant of SARS-CoV-2. The company's investigational monoclonal antibody (mAb) PEMGARDA, authorized by the U.S. Food and Drug Administration (FDA) for pre-exposure prophylaxis of COVID-19 in certain immunocompromised patients, has shown no meaningful change in its neutralizing activity against the XFG variant [1].

The data, presented by Invivyd, indicates that PEMGARDA and its next-generation mAb candidate, VYD2311, maintain consistent and highly potent neutralizing activity against the XFG variant. This stability in neutralization activity is attributed to the structural integrity of the epitopes targeted by these mAbs, which remain unchanged across various SARS-CoV-2 variants [1].

The company estimates that every clinical variant reported since the Omicron BA.2 lineage has been susceptible to PEMGARDA, underscoring the robustness of its molecular design strategy [1]. This consistent performance across multiple variants is a significant indicator of Invivyd's ability to create high-barrier-to-resistance medicines.

Invivyd's Chief Scientific Officer, Robert Allen, Ph.D., commented on the findings, stating, "The demonstrated stability of the epitopes our monoclonal antibodies target across SARS-CoV-2 evolution underscores the strength of our molecular design strategy and our capability in creating high-barrier-to-resistance medicines." Tim Lee, Chief Commercial Officer of Invivyd, added that PEMGARDA's continued activity is particularly important for individuals with compromised immune systems, who may face additional challenges during COVID-19 waves [1].

The company plans to provide the FDA with data showing the continued in vitro neutralizing activity of PEMGARDA against XFG and other circulating viruses, with the anticipated inclusion of this information in the PEMGARDA Fact Sheet for Healthcare Providers [1].

References:
[1] https://www.morningstar.com/news/globe-newswire/9514390/invivyd-announces-continued-neutralizing-activity-of-pemgarda-pemivibart-and-vyd2311-against-currently-dominant-sars-cov-2-variant-xfg-stratus